Only highest-dose iberdomide outperforms placebo in SLE; adverse events high

Iberdomide, a novel oral cereblon modulator, was superior to a placebo only in patients with systemic lupus erythematosus who received the highest dose in a phase 2 trial, albeit with a high incidence of adverse events, according to data.
“Lupus treatment development has been problematic because of the diversity of clinical manifestations and pathology in people with this same diagnosis,” Joan T. Merrill, MD, of the Oklahoma Medical Research Foundation, in Oklahoma City, and lead author of the study, told Healio. “Selection and dosing of available treatment remains largely

Iberdomide, a novel oral cereblon modulator, was superior to a placebo only in patients with systemic lupus erythematosus who received the highest dose in a phase 2 trial, albeit with a high incidence of adverse events, according to data.
“Lupus treatment development has been problematic because of the diversity of clinical manifestations and pathology in people with this same diagnosis,” Joan T. Merrill, MD, of the Oklahoma Medical Research Foundation, in Oklahoma City, and lead author of the study, told Healio. “Selection and dosing of available treatment remains largely